Loading stock data…
BNGO
$1.18+0.02 (+1.72%)
Market ClosedLast close May 1
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bionano Genomics, Inc. in the Healthcare sector is trading at $1.18. The stock is currently near its 52-week low of $1.06, remaining 38.2% below its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why BNGO maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.18
Potential Upside
5%
Whystock Fair Value$1.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.42%
Volume
Today's trading volume
92,469
Recent News
Bionano Genomics Inc (BNGO) Q4 2025 Earnings Call Highlights: Navigating Challenges with ...
Bionano Genomics Inc (BNGO) reports improved gross margins and cost management amid revenue declines, with promising growth prospects for 2026.
Bionano Genomics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Bionano Genomics, Inc.'s Q4 2025 earnings call
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?
Here is how Black Diamond (BDTX) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
Bionano Genomics Inc (BNGO) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Cost ...
Bionano Genomics Inc (BNGO) reports a 21% revenue increase and significant cost reductions, setting a strong financial outlook for the remainder of 2025.
Bionano (BNGO) Q3 2025 Earnings Call Transcript
Erik Holmlin: Thank you, Kelly, and good afternoon, everyone. At Bionano Genomics, Inc., our focus is on transforming pathology, which is the medical discipline that investigates disease, including its causes, developments, and effects. Over the last year, we have taken decisive steps to transform our business model away from one based in aggressively growing the installed base toward a model that's driving utilization of our solutions within a subset of our existing OGM and VIA software user base.